Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181604 · ClinicalTrials.gov registry record
Multicenter Symphony IL-6 Monitoring Sepsis ICU Study
A clinical trial, sponsored by Bluejay Diagnostics.
- Completed
- Registry status
- 143
- Enrollment target
NCT06181604: Completed study, sponsored by Bluejay Diagnostics.
NCT06181604 is a clinical trial that has completed, run by Bluejay Diagnostics. The registered enrollment target is 143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06181604 has completed, sponsored by Bluejay Diagnostics.
- COMPLETED
- Registry status
- 143 participants
- Enrollment target
Study Summary
The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the intensive care unit (ICU) diagnosed with sepsis or septic shock.
Primary Outcome
Participants will be followed up for 28 days for all-cause mortality
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2024-07-12 |
What the finished NCT06181604 record still lists
NCT06181604 is an observational study that tracks outcomes without assigning an intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06181604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06181604 about?
NCT06181604 is a clinical study titled "Multicenter Symphony IL-6 Monitoring Sepsis ICU Study". The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the intensive care unit (ICU) diagnosed with sepsis or septic shock.
What is the current status of trial NCT06181604?
This trial is currently completed. The enrollment target is 143 participants. The study started on 2024-01-12. Estimated completion is 2024-07-12.
Who is sponsoring clinical trial NCT06181604?
This trial is sponsored by Bluejay Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI